Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): Study protocol for an investigator-driven randomised controlled trial

BMJ Open

Volumn 5, Issue 3, 2015, Pages

  Rosso Fernández, Clara ^a   Sojo Dorado, Jesús ^a   Barriga, Angel ^a   Lavín Alconero, Lucía ^a   Palacios, Zaira ^a,b   López Hernández, Inmaculada ^a   Merino, Vicente ^b   Camean, Manuel ^b   Pascual, Alvaro ^a,c   Rodríguez Baño, Jesús ^a,b,c   Kindelán, Natera ^d   Lletí, Salavert ^e   De Lucas, Merino ^f   Prous, Amador ^g   Torres, Hernández ^h   Perujo, Shaw ⁱ   Pomar, ⁱ   Sebastián, Calvo ⁱ   Redó, Sorli ^j   Serrallach, Pigrau ^k   Gaite, Barcenilla ^l   Da Silva, Sequeira Lopes ^m   García, Pintado ⁿ   Martínez, Martínez ^o   Gutierrez, Fleites ^p   Bastarrica, Bereciartua ^q   Gutiérrez, Dueñas ^r   Álvarez, Martínez ^s   Solé, Borrell ^t   Santana, Cárdenas ^u   Negrin ^v   Fernández, Lecuona ^w   more..

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^g HOSPITAL MARINA BAIXA   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j HOSPITAL DEL MAR   (Spain)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^m HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁿ HOSPITAL RAMÓN Y CAJAL   (Spain)

^o HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^p HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^q HOSPITAL DE CRUCES   (Spain)

^r HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^s HOSPITAL ROYO VILLANOVA   (Spain)

^t HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^u Unidad de Medicina Paliative   (Spain)

^v Hospital Universitario de Burgos ^*  (Spain)

^w HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN; MEROPENEM; ANTIINFECTIVE AGENT; BETA LACTAMASE; THIENAMYCIN DERIVATIVE;

ADULT; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ETHICS; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; HUMAN; MEDICAL RESEARCH; MULTICENTER STUDY; PEER REVIEW; PHASE 3 CLINICAL TRIAL; PROFESSIONAL STANDARD; RANDOMIZED CONTROLLED TRIAL; SPAIN; STUDY DESIGN; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GRAM NEGATIVE BACTERIUM; INTESTINE; INTESTINE FLORA; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MICROBIOLOGY; MULTIDRUG RESISTANCE; URINARY TRACT INFECTIONS;

ADMINISTRATION, INTRAVENOUS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CLINICAL PROTOCOLS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FOSFOMYCIN; GASTROINTESTINAL MICROBIOME; GRAM-NEGATIVE BACTERIA; HUMANS; INTESTINES; RESEARCH DESIGN; THIENAMYCINS; URINARY TRACT INFECTIONS;

EID: 84926642077     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-007363     Document Type: Article

References (26)

1. Boucher HW, Talbot GH, Benjamin DK Jr, et al. Infectious Diseases Society of America. 10x'20 Progress development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013;56:1685-94.
2. Bettiol E, Rottier WC, Del Toro MD, et al. COMBACTE consortium. Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies. Future Microbiol 2014;9:757-71.
3. Rodríguez-Baño J, Pascual A. Clinical significance of extended-spectrum beta-lactamases. Expert Rev Anti Infect Ther 2008;6:671-83.
4. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance - the need for global solutions. Lancet Infect Dis 2013;13:1057-98.
5. Rottier WC, Ammerlaan HS, Bonten MJ, et al. Effects of confounders and intermediates on the association of bacteraemia caused by extended spectrum beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2012;67:1311-20.
6. Vidal L, Gafter-Gvili A, Borok S, et al. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2007;60:247-57.
7. Falagas ME, Maraki S, Karageorgopoulos DE, et al. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents 2010;35:240-3.
8. de Cueto M, López L, Hernández JR, et al. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother 2006;50:368-70.
9. Spanish Agency of Medicines and Medical Devices. Disodium fosfomycin (data sheet). http://www.aemps.gob.es/cima/pdfs/es/ft/54165/FT-54165 (accessed 11 Nov 2014).
10. Falagas ME, Kastoris AC, Kapaskelis AM, et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum betalactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010;10:43-50.
11. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200-7.
12. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586.
13. Pulcini C, Bush K, Craig WA, et al. Forgotten antibiotics: an inventory in Europe, the United States. Clin Infect Dis 2012;54:268-74.
14. Rex JH, Eisenstein BI, Alder J, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 2013;13:269-75.
15. Infectious Diseases Society of America. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis 2012;55:1031-46.
16. Oteo J, Bautista V, Lara N, et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother 2010;65:2459-63.
17. Karageorgopoulos DE, Wang R, Yu XH, et al. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 2010;67:255-68.
18. Retamar P, Portillo MM, López-Prieto MD, et al. SAEI/SAMPAC Bacteremia Group. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother 2012;56:472-8.
19. Roussos N, Karageorgopoulos DE, Samonis G, et al. Clinical significance of the pharmacokinetic and pharmacodynamics characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009;34:506-15.
20. Matzi V, Lindenmann J, Porubsky C, et al. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother 2010;65:995-8.
21. Parker S, Lipman J, Koulenti D, et al. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents 2013;42:289-93.
22. FDA. Complicated urinary tract infections: developing drugs for treatment. Draft guidance. February 2012.
23. Cox CE, Holloway WJ, Geckler RW. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Clin Infect Dis 1995;21:86-92.
24. Ertapenem label information. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000389/WC500033921.pdf
25. Rodríguez-Baño J, Alcalá JC, Cisneros JM, et al. Community infections caused by extended-spectrum-lactamase producing-Escherichia coli. Arch Intern Med 2008;168:1897-902.
26. Rodríguez-Baño J, Navarro MD, Retamar P, et al. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54:167-74.